Processa is no longer the oncology microcap that spent years trying to rescue capecitabine. In late July the company absorbed Vidya Therapeutics in a stock-for-stock combination and closed a large preferred private placement led by specialist healthcare funds. The surviving listed common is a thin stub. Legacy holders retain less than one percent of the fully diluted company once the new preferred converts. The live debate is whether that stub still prices the old shell or already anticipates a funded immunology franchise.
Mid-year cash had almost run out. First-half operating burn consumed most of the remaining treasury, and a leftover token position marked down through the spring. The July placement changed the solvency math overnight. Net proceeds of $183.3 million reset the runway. Management guides that cash through late 2029 and through three Phase 2 readouts. That is a different company than the one that printed a stockholders deficit at mid-year.
Second-quarter research spending collapsed after the breast-cancer study was paused, which is why the printed loss narrowed even as administrative costs rose. That print is already historical. The questions that matter now are whether holders approve preferred conversion later this year, whether the new lead molecule starts its food-allergy and urticaria studies on the advertised calendar, and whether a listed float of under three million shares continues to trade at a premium to the placement's as-converted price.